DOCSLIB.ORG

Sa Funds Investment Trust

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sa Funds Investment Trust SECURITIES AND EXCHANGE COMMISSION FORM N-Q Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q Filing Date: 2010-11-19 | Period of Report: 2010-09-30 SEC Accession No. 0001206774-10-002408 (HTML Version on secdatabase.com) FILER SA FUNDS INVESTMENT TRUST Mailing Address Business Address 3055 OLIN AVENUE SUITE 3055 OLIN AVENUE SUITE CIK:1075065| IRS No.: 770216379 | State of Incorp.:DE | Fiscal Year End: 0630 2000 2000 Type: N-Q | Act: 40 | File No.: 811-09195 | Film No.: 101204783 SAN JOSE CA 95128 SAN JOSE CA 95128 408-260-3100 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-09195 SA FUNDS - INVESTMENT TRUST (Exact name of registrant as specified in charter) 3055 Olin Avenue, Suite 2000 San Jose, California 95128 (Address of principal executive offices) (Zip Code) Steven K. McGinnis, Esq. Chief Legal Officer SA Funds - Investment Trust 3055 Olin Ave., Suite 2000 San Jose, CA. 95128 (Name and Address of Agent for Service) Copies to: Brian F. Link R. Darrell Mounts Vice President and Managing Counsel Counsel to the Trust State Street Bank and Trust Company K&L Gates LLP Mail Code: JHT 1732 1601 K Street, N.W. 200 Clarendon Street Washington, D.C. 20006 Boston, MA 02116 Registrant’s telephone number, including area code: (408) 260-3100 Date of fiscal year end: June 30 Date of reporting period: September 30, 2010 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document SA U.S. Fixed Income Fund PORTFOLIO OF INVESTMENTS — AS OF SEPTEMBER 30, 2010 (Unaudited) FACE AMOUNT VALUE† BONDS AND NOTES — 98.0% Austria — 0.8% Oesterreichische Kontrollbank AG, 4.750%, 11/08/11 USD $2,000,000 $2,091,312 Canada — 2.5% Province of Ontario Canada, 2.625%, 1/20/12 USD 5,500,000 5,640,976 Province of Ontario Canada, 4.950%, 6/01/12 USD 500,000 535,178 6,176,154 Germany — 3.2% Kreditanstalt fuer Wiederaufbau, 1.250%, 6/15/12 USD 900,000 912,307 Kreditanstalt fuer Wiederaufbau, 2.250%, 4/16/12 USD 3,000,000 3,078,597 Kreditanstalt fuer Wiederaufbau, 3.250%, 10/14/11 USD 700,000 720,832 Kreditanstalt fuer Wiederaufbau, 4.750%, 5/15/12 USD 1,700,000 1,813,818 Landeskreditbank Baden-Wuerttemberg Foerderbank, 4.875%, 1/13/12 USD 1,400,000 1,474,641 8,000,195 Japan — 2.8% Japan Finance Corp., 1.500%, 7/06/12 USD 6,800,000 6,878,826 Supranational — 4.4% European Investment Bank, 3.250%, 10/14/11 USD 5,000,000 5,148,800 International Bank for Reconstruction & Development, 0.800%, 7/13/12 USD 5,800,000 5,827,260 10,976,060 United States — 84.3% Citibank NA, 1.875%, 5/07/12 1,800,000 1,838,273 Citibank NA, 1.875%, 6/04/12 4,000,000 4,087,656 Federal Farm Credit Bank, 0.950%, 2/10/12 6,200,000 6,244,727 Federal Farm Credit Bank, 0.950%, 3/05/12 1,200,000 1,208,783 Federal Farm Credit Bank, 2.000%, 1/17/12 4,100,000 4,184,690 Federal Farm Credit Bank, 2.125%, 6/18/12 2,500,000 2,568,555 Federal Home Loan Banks, 0.875%, 8/22/12 2,000,000 2,013,656 Federal Home Loan Banks, 1.125%, 3/09/12 15,500,000 15,658,410 Federal Home Loan Banks, 1.125%, 5/18/12 9,300,000 9,401,249 Federal Home Loan Banks, 1.375%, 6/08/12 18,600,000 18,883,390 Federal Home Loan Banks, 1.750%, 8/22/12 6,500,000 6,651,307 Federal Home Loan Banks, 1.875%, 6/20/12 4,800,000 4,915,022 Federal Home Loan Mortgage Corp., 1.125%, 7/27/12 16,600,000 16,800,113 Federal Home Loan Mortgage Corp., 4.750%, 3/05/12 5,600,000 5,946,382 Federal Home Loan Mortgage Corp., 5.125%, 7/15/12 2,200,000 2,380,838 Federal Home Loan Mortgage Corp., 5.500%, 8/20/12 15,200,000 16,627,006 Federal Home Loan Mortgage Corp., 5.750%, 1/15/12 8,400,000 8,971,057 Federal National Mortgage Association, 0.875%, 1/12/12 9,000,000 9,052,524 Federal National Mortgage Association, 1.000%, 4/04/12 14,600,000 14,725,531 Federal National Mortgage Association, 1.125%, 7/30/12 5,700,000 5,765,043 Federal National Mortgage Association, 1.875%, 4/20/12 13,200,000 13,493,383 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Federal National Mortgage Association, 2.000%, 1/09/12 2,000,000 2,041,188 Federal National Mortgage Association, 4.375%, 9/15/12 6,000,000 6,448,668 Federal National Mortgage Association, 4.875%, 5/18/12 700,000 750,214 Federal National Mortgage Association, 5.000%, 2/16/12 3,000,000 3,187,374 General Electric Capital Corp., 2.200%, 6/08/12 3,800,000 3,908,156 General Electric Capital Corp., 3.000%, 12/09/11 600,000 618,404 General Electric Capital Corp., 3.500%, 8/13/12 800,000 832,476 General Electric Capital Corp., 4.375%, 3/03/12 1,450,000 1,516,279 Goldman Sachs Group, Inc., 3.250%, 6/15/12 1,000,000 1,045,918 HSBC USA, Inc., 3.125%, 12/16/11 2,900,000 2,994,630 JPMorgan Chase & Co., 2.125%, 6/22/12 4,500,000 4,627,210 JPMorgan Chase & Co., 2.200%, 6/15/12 1,000,000 1,028,745 Morgan Stanley, 1.950%, 6/20/12 1,900,000 1,947,257 Morgan Stanley, 2.250%, 3/13/12 4,500,000 4,616,820 Regions Bank, 3.250%, 12/09/11 3,000,000 3,098,298 210,079,232 TOTAL BONDS AND NOTES (Identified Cost $242,583,587) 244,201,779 SHORT-TERM INVESTMENTS — 2.0% SHARES VALUE† Other — 2.0% SSgA Government Money Market Fund 1 1 SSgA Money Market Fund 5,032,287 5,032,287 5,032,288 TOTAL SHORT-TERM INVESTMENTS (Identified Cost $5,032,288) 5,032,288 Total Investments — 100.0% (Identified Cost $247,615,875)# 249,234,067 Cash and Other Assets, Less Liabilities — 0.0% 66,339 Net Assets — 100.0% $249,300,406 ____________________ † See Note 1. # At September 30, 2010 the aggregate cost of investment securities for income tax purposes was $247,615,875. Net unrealized appreciation aggregated $1,618,192 of which $1,635,833 related to appreciated investment securities and $17,641 related to depreciated investment securities. Key to abbreviations: USD — U.S. Dollar See notes to schedule of investments. Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document SA U.S. Fixed Income Fund September 30, 2010 Portfolio Sectors (% of portfolio market value) Sector Percentage U.S. Government Agency 71.4 % Financials 16.4 % Government Sponsored 5.8 % Supranational 4.4 % Short - Term 2.0 % Total 100.0 % Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document SA Global Fixed Income Fund PORTFOLIO OF INVESTMENTS — AS OF SEPTEMBER 30, 2010 (Unaudited) FACE AMOUNT VALUE† BONDS AND NOTES — 98.9% Australia — 9.4% Australia & New Zealand Banking Group, 4.375%, 5/24/12 EUR 3,500,000 $4,988,602 General Electric Capital Australia Funding Pty Ltd., 7.500%, 1/25/11 AUD 13,000,000 12,621,525 National Australia Bank Ltd., 5.375%, 12/08/14 GBP 1,500,000 2,627,544 Suncorp-Metway Ltd., 4.000%, 1/16/14 GBP 7,000,000 11,788,469 Westpac Banking Corp., 2.900%, 9/10/14 USD 5,000,000 5,295,285 Westpac Banking Corp., 3.000%, 8/04/15(a) USD 2,000,000 2,045,012 Westpac Banking Corp., 3.750%, 12/01/14 CAD 6,000,000 5,975,916 45,342,353 Austria — 3.7% Austria Government International Bond, 3.250%, 6/25/13 USD 4,000,000 4,256,128 Pfandbriefstelle der Oesterreichischen Landes-Hypothekenbanken, 1.600%, 2/15/11 JPY 1,150,000,000 13,802,342 18,058,470 Belgium — 2.7% Belgium Government International Bond, 2.750%, 3/05/15(a) USD 1,000,000 1,034,871 Belgium Government International Bond, 4.250%, 9/03/13, 144A USD 11,000,000 11,880,330 12,915,201 Canada — 14.8% Bank of Nova Scotia, 3.430%, 7/16/14 CAD 2,000,000 2,012,771 Canada Housing Trust No 1, 2.750%, 12/15/14 CAD 14,000,000 13,994,421 Export Development Canada, 4.500%, 10/25/12 USD 5,000,000 5,400,010 Ontario Electricity Financial Corp., 7.450%, 3/31/13 USD 9,400,000 10,919,689 Province of Alberta Canada, 2.750%, 12/01/14 CAD 13,800,000 13,793,830 Province of British Columbia Canada, 4.300%, 5/30/13(a) USD 3,000,000 3,280,599 Province of Ontario Canada, 4.100%, 6/16/14 USD 9,800,000 10,774,933 Province of Ontario Canada, 4.400%, 12/02/11 CAD 1,000,000 1,005,414 Royal Bank of Canada, 4.970%, 6/05/14 CAD 6,000,000 6,364,467 Royal Bank of Canada, 5.060%, 7/17/13 CAD 4,000,000 4,206,434 71,752,568 France — 8.5% Agence Francaise de Developpement, 5.125%, 4/25/12 EUR 7,670,000 11,081,156 Caisse d'Amortissement de la Dette Sociale, 5.250%, 10/25/12 EUR 7,250,000 10,707,686 Societe Financement de l'Economie Francaise, 2.875%, 9/22/14 USD 8,500,000 8,979,663 Total Capital SA, 5.625%, 1/25/12 AUD 10,900,000 10,563,995 41,332,500 Germany — 5.8% Kreditanstalt fuer Wiederaufbau, 3.125%, 12/08/14 GBP 1,000,000 1,649,303 Kreditanstalt fuer Wiederaufbau, 4.000%, 10/15/13(a) USD 5,000,000 5,456,750 Kreditanstalt fuer Wiederaufbau, 4.125%, 10/15/14 USD 1,000,000 1,109,033 Kreditanstalt fuer Wiederaufbau, 4.625%, 10/12/12 EUR 4,000,000 5,836,958 Landesbank Hessen-Thueringen Girozentrale, 3.000%, 10/18/12 CHF 2,000,000 2,133,840 Copyright © 2012 www.secdatabase.com.
Load more

Recommended publications
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • Fidelity® Extended Market Index Fund
    Quarterly Holdings Report for Fidelity® Extended Market Index Fund May 31, 2021 SEI-QTLY-0721 1.816014.116 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.8% Shares Value Shares Value COMMUNICATION SERVICES – 6.0% CarGurus, Inc. Class A (a) 481,276 $ 13,581,609 Diversified Telecommunication Services – 0.5% Cars.com, Inc. (a) 356,794 5,212,760 Alaska Communication Systems Group, Inc. 306,734 $ 1,018,357 Creatd, Inc. (a) (b) 42,672 156,606 Anterix, Inc. (a) (b) 65,063 3,218,016 DHI Group, Inc. (a) 262,377 839,606 ATN International, Inc. 49,421 2,336,131 Eventbrite, Inc. (a) (b) 368,036 7,471,131 Bandwidth, Inc. (a) (b) 118,706 14,041,733 EverQuote, Inc. Class A (a) (b) 54,748 1,726,204 Cincinnati Bell, Inc. (a) 265,617 4,090,502 IAC (a) 439,438 70,077,178 Cogent Communications Group, Inc. (b) 226,643 17,134,211 Izea Worldwide, Inc. (a) 258,392 718,330 Consolidated Communications Holdings, Inc. (a) 325,131 3,043,226 Kubient, Inc. (b) 44,094 228,848 Cuentas, Inc. (a) (b) 48,265 108,596 Liberty TripAdvisor Holdings, Inc. (a) 380,876 1,812,970 Globalstar, Inc. (a) (b) 3,272,215 5,235,544 Match Group, Inc. (a) 1,417,570 203,251,187 IDT Corp. Class B (a) 96,642 2,789,088 MediaAlpha, Inc. Class A (b) 91,323 3,864,789 Iridium Communications, Inc. (a) 621,382 23,743,006 Pinterest, Inc. Class A (a) 2,805,904 183,225,531 Liberty Global PLC: Professional Diversity Network, Inc.
    [Show full text]
  • ANGEBOTSUNTERLAGE Freiwilliges Öffentliches
    Pflichtveröffentlichung gemäß §§ 34, 14 Abs. 2 und 3 Wertpapiererwerbs- und Übernahmegesetz (WpÜG) Aktionäre der WMF Württembergische Metallwarenfabrik Aktiengesellschaft, insbesondere mit Wohnsitz, Sitz oder gewöhnlichem Aufenthalt außerhalb der Bundesrep ublik Deutschland, sollten die Hinweise in Abschnitt 1 "Allgemeine Hinweise, insbesondere für Aktionäre mit Wohnsitz, Sitz oder gewöhnlichem Aufenthalt außerhalb der Bundesrepublik Deutschland" auf den Seiten 4 ff. dieser Angebotsunterlage sowie in Abschnitt 23 "Wichtige Hinweise für US-Aktionäre" auf den Sei- ten 48 ff. dieser Angebotsunterlage besonders beachten. ANGEBOTSUNTERLAGE Freiwilliges öffentliches Übernahmeangebot (Barangebot) der Finedining Capital GmbH Leopoldstraße 8-10, 80802 München, Deutschland an die Aktionäre der WMF Württembergische Metallwarenfabrik Aktiengesellschaft Eberhardstraße 17-47, 73309 Geislingen an der Steige, Deutschland zum Erwerb ihrer auf den Inhaber lautenden Stammaktien und ihrer auf den Inhaber lautenden Vor- zugsaktien an der WMF Württembergische Metallwarenfabrik Aktiengesellschaft gegen Zahlung einer Geldleistung in Höhe von EUR 47,00 je Stammaktie und EUR 31,80 je Vorzugsaktie der WMF Württembergische Metallwarenfabrik Aktiengesellschaft Die Annahmefrist läuft vom 16. August 2012 bis 20. September 2012, 24:00 Uhr (Ortszeit Frankfurt am Main) / 18:00 Uhr (Ortszeit New York) Aktien der WMF Württembergische Metallwarenfabrik Aktiengesellschaft: International Securities Identification Number (ISIN) DE0007803009 (Stammaktien) und DE0007803033 (Vorzugsaktien)
    [Show full text]
  • Helping People Look and Feel Their Best Alliance Boots Annual Report 2013/14 We Are a Leading International Pharmacy-Led Health and Beauty Group
    Alliance Boots Alliance Annual Report 2013/14 Report Annual Helping people look and feel their best Alliance Boots Annual Report 2013/14 We are a leading international pharmacy-led health and beauty group. Our focus is on helping people look and feel their best. What’s inside Strategic review Our financial performance in 2013/14 01 Executive Chairman’s statement 02 Our mission, purpose and values 05 Our Group at a glance 06 Our business activities 08 Group strategy and objectives 10 Our markets and business environment 14 Our financial record 16 Business review: Overview 18 Health & Beauty Division 20 Pharmaceutical Wholesale Division 28 Other activities 34 Financial review 36 Performance measures 42 We are launching innovative Our people 43 new products tailored to meet Corporate social responsibility 46 customer needs page 12 Governance Boots much loved brands are Board of Directors 50 increasingly available across Board report on corporate governance 54 the world page 26 Board report on remuneration 56 Audit and risk committee report 59 Risk management 60 Consolidated financial statements Directors’ responsibilities statement 62 Statutory auditor’s report 63 Group income statement 64 Group statement of comprehensive income 64 Group statement of financial position 65 Group statement of changes in equity 66 Group statement of cash flows 67 Notes to the consolidated financial statements 68 Additional information Principal businesses, associates and joint ventures 120 Glossary of key terms 123 Alphega is expanding its Supporting the fight against pharmacy network cancer page 44 across Europe page 32 Alliance Boots | Annual Report 2013/14 01 Strategic review Our financial performance in 2013/14 Strategic review for the year ended 31 March 2014 Underlying profit attributable to equity shareholders increased by 18.5%.
    [Show full text]
  • Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote
    As of 4/23/2013 Schedule subject to change Monday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room April 22 Merck KLOX Technologies Immune Design 1:00 PM Leading Biotech/Big Pharma Medical Devices Vaccines Eli Lilly NewSouth Innovations Syntiron 1:15 PM Leading Biotech/Big Pharma University/Academia Vaccines Amgen Radius Health BioCrea 1:30 PM Leading Biotech/Big Pharma Musculoskeletal Neurology/CNS Nat. Inst. of Neurological Dis. & Stroke Cytokinetics Xenon Pharmaceuticals 1:45 PM Neurology/CNS Musculoskeletal Neurology/CNS Curis OrgaNext Research BV Trigemina 2:00 PM Oncology Regenerative Medicine Neurology/CNS Verastem Flexion Therapeutics Neurocrine Biosciences 2:15 PM Oncology Musculoskeletal Hormone Therapy/CNS Michael J. Fox Foundation Antisense Pharma GmbH Versartis 2:30 PM Non-profit/Patient Advocacy Oncology Hormone Therapy Takeda Pharmaceutical Company TBD KODE Biotech 2:45 PM Leading Biotech/Big Pharma Drug Delivery Resverlogix Corp. Advaxis Q Chip 3:00 PM Cardiovascular Disease Oncology Drug Delivery Grünenthal GmbH Array BioPharma 3:15 PM Neurology/CNS Oncology/Drug Discovery Discovery Labs Mersana Therapeutics 3:30 PM Drug Delivery/Pulmonary Oncology Bayer HealthCare Igenica 3:45 PM Leading Biotech/Big Pharma Oncology Presentations are open to all Convention attendees and are located outside the main entrance of the BIO Business Forum As of 4/23/2013 - Schedule subject to change Tuesday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Chicago Blackhawks Room April 23 Pfizer 8:00 AM Leading Biotech/Big Pharma
    [Show full text]
  • At the Heart of Health Corporate Social Responsibility Report
    2020 At the Heart of Health Corporate Social Responsibility Report #WeAreWBA We are a leading global pharmacy retailer and wholesaler. As a health and well-being enterprise our purpose is to help people across the world lead healthier and happier lives. At the Heart of Health is our annual Corporate Social Responsibility report, covering our CSR initiatives, sustainability progress and Environmental, Social and Governance (ESG) performance for the fiscal year ended Aug. 31, 2020. OVERVIEW HEALTHY PLANET Message from Our Leaders 4 Energy and Emissions 85 Q&A with Our CSR Committee Chair 6 Waste and Plastics 94 Our Vision, Purpose and Values 8 Case Study: Honeybees on Campus 100 At a Glance: WBA 9 SUSTAINABLE MARKETPLACE Highlights and Recognitions 10 Progress Dashboard 12 Sustainability Progress in Our Owned Brands 103 Our Approach to CSR 15 Sourcing 106 CSR Materiality 24 Ingredients, Materials and Traceability 111 Stakeholder Engagement 28 Packaging, Labeling and Transparency 114 Our Response to COVID-19 38 Case Study: Removing Plastics from Boots UK Gift Product Lines 117 Our Response to the Racial Equity Movement 46 Brands with Purpose 118 HEALTHY AND INCLUSIVE WORKPLACE HEALTHY COMMUNITIES Employee Health, Well-being and Safety 123 Access to Affordable and Quality Healthcare 51 Equal Opportunities 134 Health Education and Awareness 61 Case Study: Unconscious Bias Training 145 Opioid Abuse Prevention 70 Data Privacy and Information Security 146 Partnerships for Good: 71 APPENDICES Supporting People Living with Cancer 72 About This Report
    [Show full text]
  • SA FUNDS INVESTMENT TRUST Form N-Q Filed 2016-11-23
    SECURITIES AND EXCHANGE COMMISSION FORM N-Q Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q Filing Date: 2016-11-23 | Period of Report: 2016-09-30 SEC Accession No. 0001206774-16-007593 (HTML Version on secdatabase.com) FILER SA FUNDS INVESTMENT TRUST Mailing Address Business Address 10 ALMADEN BLVD, 15TH 10 ALMADEN BLVD, 15TH CIK:1075065| IRS No.: 770216379 | State of Incorp.:DE | Fiscal Year End: 0630 FLOOR FLOOR Type: N-Q | Act: 40 | File No.: 811-09195 | Film No.: 162016544 SAN JOSE CA 95113 SAN JOSE CA 95113 (800) 366-7266 Copyright © 2016 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-09195 SA FUNDS - INVESTMENT TRUST (Exact name of registrant as specified in charter) 10 Almaden Blvd., 15th Floor, San Jose, CA 95113 (Address of principal executive offices) (Zip Code) Deborah Djeu Chief Compliance Officer SA Funds - Investment Trust 10 Almaden Blvd., 15th Floor, San Jose, CA 95113 (Name and Address of Agent for Service) Copies to: Brian F. Link Mark D. Perlow, Esq. Vice President and Managing Counsel Counsel to the Trust State Street Bank and Trust Company Dechert LLP 100 Summer Street One Bush Street, Suite 1600 7th Floor, Mailstop SUM 0703 San Francisco, CA 94104-4446 Boston, MA 02111 Registrants telephone number, including area code: (800) 366-7266 Date of fiscal year end: June 30 Date of reporting period: September 30, 2016 Copyright © 2013 www.secdatabase.com.
    [Show full text]
  • Walgreens Boots Alliance, Inc. 2017 Annual Report
    PART I Item 1. Business Overview Walgreens Boots Alliance, Inc., a Delaware corporation (“Walgreens Boots Alliance”) is the first global, pharmacy-led health and wellbeing enterprise with sales of $118.2 billion in the fiscal year ended August 31, 2017. Our purpose is to help people across the world lead healthier and happier lives. Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination across the U.S. and Europe. Walgreens Boots Alliance and the companies in which it has equity method investments together have a presence in more than 251 countries and employ more than 385,0001 people. The company is a global leader in pharmacy-led, health and wellbeing retail and, together with the companies in which it has equity method investments, has over 13,2001 stores in 111 countries as well as one of the largest global pharmaceutical wholesale and distribution networks, with over 3901 distribution centers delivering to more than 230,0002 pharmacies, doctors, health centers and hospitals each year in more than 201 countries. In addition, Walgreens Boots Alliance is one of the world’s largest purchasers of prescription drugs and many other health and wellbeing products. Our portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as increasingly global health and beauty product brands, such as No7, Soap & Glory, Liz Earle, Sleek MakeUP and Botanics. Our global brands portfolio is enhanced by our in-house product research and development capabilities. We seek to further drive innovative ways to address global health and wellness challenges.
    [Show full text]
  • Semi-Annual Report 31 March 2015 United Kingdom
    Schroder GAIA Semi-Annual Report 31 March 2015 United Kingdom R.C.S. Luxembourg B 148.818 Schroder GAIA Société d’Investissement à Capital Variable (SICAV) Semi-Annual Report 31 March 2015 No subscriptions can be received on the basis of periodical reports. Subscriptions are valid only if made on the basis of the current prospectus accompanied by the last available annual report or semi-annual report if published thereafter. Annual and semi-annual reports, the current prospectus and the Articles of Incorporation of Strategic Solutions (the ‘Company’) are available, free of charge, at the Company’s registered office, 5, rue Höhenhof, L-1736 Senningerberg, Grand Duchy of Luxembourg. Schroder GAIA Semi-Annual Report 31 March 2015 Page 5 Contents Schroder GAIA ...................................... 7 Information Addressed to UK Investors .................. 8 Board of Directors ................................... 9 Administration ...................................... 10 Directors’ Report .................................... 11 Investment Manager’s Report .......................... 12 Notes to the Financial Statements ...................... 13 Statement of Net Assets .............................. 29 Distribution of Investments by Industry . 33 Portfolio of Investments Schroder GAIA Cat Bond . 35 Schroder GAIA Egerton Equity . 36 Schroder GAIA Global Macro Bond . 37 Schroder GAIA KKR Credit * . 39 Schroder GAIA Paulson Merger Arbitrage . 40 Schroder GAIA QEP Global Absolute . 40 Schroder GAIA Sirios US Equity . 46 Appendix I - TER .................................... 47 * Please refer to the Directors' Report for the details of all corporate actions that occurred during the period under review. Schroder GAIA Semi-Annual Report 31 March 2015 Page 7 Schroder GAIA The Company Schroder GAIA (the ‘Company’) is an umbrella structured open-ended investment company with limited liability, organised as a ‘société anonyme’ and qualifies as a SICAV under Part I of the Law of 17 December 2010 amended.
    [Show full text]
  • Dimensional Funds PLC
    Dimensional Funds PLC Semi-Annual Report and Accounts 31 May 2012 Authorised and Regulated by the Financial Services Authority 1 No marketing notification has been submitted in Germany for the following sub-funds of Dimensional Funds PLC: European Core Equity Fund Sterling Inflation Linked Intermediate Duration Fixed Income Fund Sterling Inflation Linked Long Duration Fixed Income Fund U.S. Value Fund Sterling Ultra Short Fixed Income Fund Multi-Factor Conservative Fund Multi-Factor Balanced Fund Accordingly, these sub-funds must not be publicly marketed in Germany. 1 DIMENSIONAL FUNDS PLC Table of Contents Page General Information..................................................................................................................................................................................................................... 2 Investment Manager’s Reports .................................................................................................................................................................................................... 3 Balance Sheet ............................................................................................................................................................................................................................. 12 Profit and Loss Account............................................................................................................................................................................................................. 16 Statement
    [Show full text]
  • International Smallcap Separate Account As of July 31, 2017
    International SmallCap Separate Account As of July 31, 2017 SCHEDULE OF INVESTMENTS MARKET % OF SECURITY SHARES VALUE ASSETS AUSTRALIA INVESTA OFFICE FUND 2,473,742 $ 8,969,266 0.47% DOWNER EDI LTD 1,537,965 $ 7,812,219 0.41% ALUMINA LTD 4,980,762 $ 7,549,549 0.39% BLUESCOPE STEEL LTD 677,708 $ 7,124,620 0.37% SEVEN GROUP HOLDINGS LTD 681,258 $ 6,506,423 0.34% NORTHERN STAR RESOURCES LTD 995,867 $ 3,520,779 0.18% DOWNER EDI LTD 119,088 $ 604,917 0.03% TABCORP HOLDINGS LTD 162,980 $ 543,462 0.03% CENTAMIN EGYPT LTD 240,680 $ 527,481 0.03% ORORA LTD 234,345 $ 516,380 0.03% ANSELL LTD 28,800 $ 504,978 0.03% ILUKA RESOURCES LTD 67,000 $ 482,693 0.03% NIB HOLDINGS LTD 99,941 $ 458,176 0.02% JB HI-FI LTD 21,914 $ 454,940 0.02% SPARK INFRASTRUCTURE GROUP 214,049 $ 427,642 0.02% SIMS METAL MANAGEMENT LTD 33,123 $ 410,590 0.02% DULUXGROUP LTD 77,229 $ 406,376 0.02% PRIMARY HEALTH CARE LTD 148,843 $ 402,474 0.02% METCASH LTD 191,136 $ 399,917 0.02% IOOF HOLDINGS LTD 48,732 $ 390,666 0.02% OZ MINERALS LTD 57,242 $ 381,763 0.02% WORLEYPARSON LTD 39,819 $ 375,028 0.02% LINK ADMINISTRATION HOLDINGS 60,870 $ 374,480 0.02% CARSALES.COM AU LTD 37,481 $ 369,611 0.02% ADELAIDE BRIGHTON LTD 80,460 $ 361,322 0.02% IRESS LIMITED 33,454 $ 344,683 0.02% QUBE HOLDINGS LTD 152,619 $ 323,777 0.02% GRAINCORP LTD 45,577 $ 317,565 0.02% Not FDIC or NCUA Insured PQ 1041 May Lose Value, Not a Deposit, No Bank or Credit Union Guarantee 07-17 Not Insured by any Federal Government Agency Informational data only.
    [Show full text]